S-Cubed Capital
VC Fund
Menlo Park, United States
S-Cubed Capital is a diversified investment holding company and family office located in Menlo Park, CA. The organization has global interests in agribusiness, financial asset management, philanthropy and real estate. Our investment portfolio is comprised of direct investments as well as partnerships with many leading investment managers.
- Total investments:
- 21
- Last investment:
- Lead investor:
- 5%
Last updated:
For AI agents: llms.txt
Industries S-Cubed Capital invests in
SaaSSoftwareEducationHealth CareBiotechnology
Stages S-Cubed Capital invests in
SeedSeries CSeries DSeries AFunding Round
Countries S-Cubed Capital invests in
United StatesIreland
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Margo Doyle
|
|||
Mark Stevens
|
|||
Investment Focus
Industry
- SaaS 4 (19%)
- Software 4 (19%)
- Education 3 (14%)
- Health Care 3 (14%)
- Biotechnology 3 (14%)
Stage
- Seed 6 (29%)
- Series C 5 (24%)
- Series D 3 (14%)
- Series A 2 (10%)
- Funding Round 2 (10%)
Country
- United States 14 (67%)
- Ireland 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Margo Doyle
Chief Investment Officer
|
Chief Investment Officer | Total investments: 2 | Find email | |
|
Mark Stevens
Managing Partner & Founder
|
Managing Partner & Founder | Total investments: 15 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Antheia
|
Antheia is unlocking the medicinal power of nature. Its synthetic biology platform surpasses the limits of conventional drug discovery and manufacturing through a novel approach to whole-cell engineering —reconstructing complex molecules in yeast to bring to market next-generation plant-inspired medicines. | $56M / Series C / Jun 03, 2025 | |
Zact
|
Businesses of all sizes struggle to find an integrated payments solution that accurately reports and reconciles expenditures at scale, within policy and budget constraints while providing a satisfactory user experience.Zact allows you to manage spend and enforces budget and policy before the spend happens. Zact’s payment platform provides acomprehensive suite of application services which support Zact and 3rd-party applications spanning every spend management use-case including expense management, payroll, product purchase, last mile delivery, BNPL and several others. Built on the payments platform is a suite of interoperable spend-management applications that integrates directly with payment networks & accounting systems.Zact completely does away with expense reports as we know it, mapping transactions at a network level to expenses and finally to the chart of accounts in accounting systems. This enables a continuous reconciliation between payments and expenses, providing accounting systems immediate visibility into expenses | Convertible Note / Jun 01, 2021 | |
NVdrones
|
NVdrones provides AI software to manage drone operations for businesses. It give drone businesses the tools to easily know what happened before, during, and after each flight. | $50K / Seed / May 01, 2021 | |
Decibel Therapeutics
|
Decibel Therapeutics is a developer of hearing disorder therapeutics intended to protect, repair and restore hearing. The company's therapeutics have provided insights into the link between hearing dysfunction and inner ear pathology and it has capabilities to encompass animal models, drug delivery to the inner ear, imaging, inner earPK/PD modeling and measurement, bioinformatics, genetics and target identification, enabling patients to experience hearing loss therapies with different forms of hearing disorders for their recovery. | $82.2M / Series D / Nov 09, 2020 | |
Innovium
|
Innovium was founded with a focus on developing and deploying advanced technology that successfully addresses the most challenging issues facing data centers. As a technology-driven company, they pride themselves on creating leading-edge innovation that aims to shatter generally accepted limits, delivering breakthrough results for their customers.The company is backed by leading venture capital firms including Greylock Partners, Walden Riverwood, Capricorn Investment Group, Qualcomm Ventures, S-Cubed Capital, and Redline Capital. | $170M / Series F / Jul 21, 2020 | |
Pliant Therapeutics
|
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that it is developing for the treatment of idiopathic pulmonaryfibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting two Phase 2a trials of PLN-74809 for the treatment of IPF and plans to initiate a Phase 2a trial in PSC in the second half of 2020. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. | $100.4M / Series C / Mar 03, 2020 | |
Future Finance
|
Future Finance is a non-government lender that offers student loans.Its mission is to provide loans for students that are simple, straightforward, and based on where they're heading, not where they've been. Future Finance helps students focus on what matters. Therefore, it aims to ensure everyone has the freedom to focus on theirstudies or kickstart their career whatever their financial background may be. It was founded in 2014 by Brian Norton and Vishal Garg and is headquartered in Dublin. | $25.8M / Series D / Jul 09, 2019 | |
|
Pliant Therapeutics
|
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that it is developing for the treatment of idiopathic pulmonaryfibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting two Phase 2a trials of PLN-74809 for the treatment of IPF and plans to initiate a Phase 2a trial in PSC in the second half of 2020. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. | $62M / Series B / Jul 16, 2018 | |
|
Decibel Therapeutics
|
Decibel Therapeutics is a developer of hearing disorder therapeutics intended to protect, repair and restore hearing. The company's therapeutics have provided insights into the link between hearing dysfunction and inner ear pathology and it has capabilities to encompass animal models, drug delivery to the inner ear, imaging, inner earPK/PD modeling and measurement, bioinformatics, genetics and target identification, enabling patients to experience hearing loss therapies with different forms of hearing disorders for their recovery. | $55M / Series C / Jun 19, 2018 | |
|
Innovium
|
Innovium was founded with a focus on developing and deploying advanced technology that successfully addresses the most challenging issues facing data centers. As a technology-driven company, they pride themselves on creating leading-edge innovation that aims to shatter generally accepted limits, delivering breakthrough results for their customers.The company is backed by leading venture capital firms including Greylock Partners, Walden Riverwood, Capricorn Investment Group, Qualcomm Ventures, S-Cubed Capital, and Redline Capital. | $77M / Series D / Apr 25, 2018 | |
| See all 21 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
SaaS Investors
112,472 investors
Software Investors
55,440 investors
Health Care Investors
47,147 investors
Biotech Investors
23,541 investors
Biotechnology Investors
20,889 investors
EdTech Investors
20,671 investors
Education Investors
15,441 investors
SaaS VC Funds
69,112 investors
Software VC Funds
35,389 investors
FAQ
What does S-Cubed Capital invest in?
S-Cubed Capital invests primarily in SaaS, Software and Education startups, most often at Seed and Series C stage. Most of the 21 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact S-Cubed Capital?
Public channels for S-Cubed Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at S-Cubed Capital?
The team at S-Cubed Capital includes Margo Doyle (Chief Investment Officer) and Mark Stevens (Managing Partner & Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
